Aurinia’s drug to treat autoimmune kidney disease hits its goals in late-stage trial

Aurinia Pharmaceuticals (AUPH) said Wednesday evening that an experimental medicine used to treat patients with lupus nephritis, an autoimmune kidney disease, achieved all primary and secondary efficacy goals in a late-stage clinical trial.